еНаука - преглед

Преглед према Аутор Giovannoni, Gavin

Приказ резултата 1 до 8 од 8
ГодинаНасловАутор(и)Тип резултатаМп-кат.
2016Alemtuzumab improves preexisting disability in active relapsing-remitting MS patientsGiovannoni, Gavin; Cohen, Jeffrey A.; Coles, Alasdair J.; Hartung, Hans-Peter; Havrdova, Eva; Selmaj, Krzysztof W.; Margolin, David H.; Lake, Stephen L.; Kaup, Susan M.; Panzara, Michael A.;
Compston, D. Alastair S.;
Научни чланак
21aM21a - Рад у међ. часопису изузетних вредности
2012Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialCohen, Jeffrey A; Coles, Alasdair J; Arnold, Douglas L; Confavreux, Christian; Fox, Edward J; Hartung, Hans-Peter; Havrdova, Eva; Selmaj, Krzysztof W; Weiner, Howard L; Fisher, Elizabeth;
Brinar, Vesna V; Giovannoni, Gavin; Stojanovic, Miroslav; Ertik, Bella I; Lake, Stephen L; Margolin, David H; Panzara, Michael A; Compston, D Alastair S;
Научни чланак
21aM21a - Рад у међ. часопису изузетних вредности
2012Effect of Alemtuzumab vs. Rebif (R) on Brain MRI Measurements: Results of CARE-MS I, a Phase 3 StudyArnold, Douglas L; Brinar, Vesna; Cohen, Jeffrey; Coles, Alasdair; Confavreux, Christian; Fisher, Elizabeth; Fox, Edward; Giovannoni, Gavin; Hartung, Hans; Havrdova, Eva;
Selmaj, Krzysztof; Weiner, Howard; Stojanovic, Miroslav; Lake, Stephen; Margolin, David; Panzara, Michael; Compston, Alastair;
Конференцијски рад
Мп категорија ће бити приказана накнадно.
2012Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif (R) Efficacy in Multiple Sclerosis I (CARE-MS I): A Phase 3 Study in Relapsing-Remitting Treatment-Naive PatientsColes, Alasdair; Brinar, Vesna; Arnold, Douglas L; Cohen, Jeffrey; Confavreux, Christian; Fox, Edward; Hartung, Hans; Havrdova, Eva; Selmaj, Krzysztof; Weiner, Howard;
Giovannoni, Gavin; Stojanovic, Miroslav; Lake, Stephen; Margolin, David; Panzara, Michael; Compston, Alastair;
Конференцијски рад
Мп категорија ће бити приказана накнадно.
2012Infections in Phase 3 Study: Comparison of Alemtuzumab and Rebif (R) Efficacy in Multiple Sclerosis I (CARE-MS I)Havrdova, Eva; Arnold, Douglas L; Cohen, Jeffrey; Coles, Alasdair; Confavreux, Christian; Fox, Edward; Hartung, Hans; Selmaj, Krzysztof; Weiner, Howard; Brinar, Vesna;
Giovannoni, Gavin; Stojanovic, Miroslav; Lake, Stephen; Margolin, David; Oyuela, Pedro; Panzara, Michael; Compston, Alastair;
Конференцијски рад
Мп категорија ће бити приказана накнадно.
2019International consensus on quality standards for brain health-focused care in multiple sclerosis (✓)Hobart, Jeremy; Bowen, Amy; Pepper, George; Crofts, Harriet; Eberhard, Lucy; Berger, Thomas; Boyko, Alexey; Boz, Cavit; Butzkueven, Helmut; Celius, Elisabeth Gulowsen;
Drulović, Jelena  ; Flores, José; Horáková, Dana; Lebrun-Frénay, Christine; Marrie, Ruth Ann; Overell, James; Piehl, Fredrik; Rasmussen, Peter Vestergaard; Sá, Maria José; Sîrbu, Carmen-Adella; Skromne, Eli; Torkildsen, Øivind; van Pesch, Vincent; Vollmer, Timothy; Zakaria, Magd; Ziemssen, Tjalf; Giovannoni, Gavin;
Научни чланак
21M21 - Рад у врхунском међ. часопису
2012Relapse Outcomes with Alemtuzumab vs. Rebif (R) in Treatment-Naive Relapsing-Remitting Multiple Sclerosis (CARE-MS I): Secondary and Tertiary EndpointsFox, Edward; Arnold, Douglas L; Brinar, Vesna; Cohen, Jeffrey; Coles, Alasdair; Confavreux, Christian; Giovannoni, Gavin; Hartung, Hans; Havrdova, Eva; Selmaj, Krzysztof;
Stojanovic, Miroslav; Weiner, Howard; Lake, Stephen; Margolin, David; Panzara, Michael; Compston, Alastair;
Конференцијски рад
Мп категорија ће бити приказана накнадно.
2015Serum neurofilament light chain levels are increased in patients with a clinically isolated syndromeDisanto, Giulio; Adiutori, Rocco; Dobson, Ruth; Martinelli, Vittorio; Dalla, Costa Gloria; Runia, Tessel; Evdoshenko, Evgeniy; Thouvenot, Eric; Trojano, Maria; Norgren, Niklas;
Teunissen, Charlotte; Kappos, Ludwig; Giovannoni, Gavin; Kuhle, Jens;
Научни чланак
21aM21a - Рад у међ. часопису изузетних вредности